On November 23, 2021, Fuzhou Maixin Biotechnology Development Co., Ltd. (referred to as “Maixin Biotech”), which focuses on the research, development, and production of specialized tumor pathology products, and Precision Scientific (Beijing) Co., Ltd. (referred to as “Precision Scientific”), which specializes in providing differentiated R&D strategies for innovative drugs, announced a strategic partnership. Through this collaboration, both parties will integrate their respective advantageous resources to engage in comprehensive and in-depth cooperation in technology and application areas such as genetic testing and immunohistochemistry. They will jointly establish a molecular diagnostic central laboratory and advance their cooperation with drug development enterprises, aiming to shorten the R&D cycle of oncology drugs and improve the success rate of R&D.
For many years, Maixin has focused on the field of tumor pathology diagnosis, specializing in the research, development, and production of immunohistochemistry reagents and instruments. It has now established antibody (mouse/rabbit) R&D platforms, diagnostic reagent development platforms, and automated instrument development platforms. Maixin has independently developed over a hundred high-performance diagnostic-grade monoclonal antibodies and has made significant progress in companion diagnostic biomarkers closely related to tumor treatment. Mr. Wang Xiaoya, Co-founder and Chairman of Maixin Biotech, expressed high expectations for the collaboration between the two parties:“With the continuous development of more targeted drugs and biomarkers, the industry of tumor targeted therapy and its companion diagnostics is entering a fast lane. Maixin will continue to uphold the philosophy of ‘Professionalism, Pragmatism, and Progress,’ always committed to promoting the development of tumor precision medicine, and providing a wide range of users with more high-quality diagnostic and companion diagnostic products and services that are synchronized with the world.”Precision Scientific has rich and successful experience in assisting pharmaceutical companies in building innovative and differentiated drug R&D pipelines.We hope to integrate the advantageous resources of both parties in the academic and industrial fields of precision medicine with Precision Scientific, working together to help every patient achieve precise and personalized treatment as soon as possible.” Utilizing its self-developed, internationally advanced multi-omics data mining platform AIBERT, which took several years to develop, Precision Scientific has successfully provided key decision-making support for the R&D of multiple pharmaceutical partners, aiding the development of several innovative drugs. In this collaboration, Precision Scientific will leverage its unique and advanced AIBERT platform to integrate the technologies and databases of both parties, forming a richer cancer omics database. Based on the AIBERT platform, data mining and bioinformatics analysis will be conducted to achieve new drug R&D based on multi-omics data mining, providing pharmaceutical companies with a novel R&D service model in translational medicine. Dr. Ji Xuwo, Founder and CEO of Precision Scientific, stated:“Source innovation in new drug R&D is a significant challenge to the industry. In clinical tumor pathology diagnosis, immunohistochemistry (IHC) is a very important technology and method, providing objective and reliable evidence for new drug R&D. Adhering to the philosophy of ‘multi-omics data mining-driven R&D,’ Precision Scientific has been continuously exploring innovative models to assist in tumor new drug R&D. Maixin Biotech is a seasoned leading enterprise in the specialized field of tumor pathology diagnosis in China. We look forward to in-depth cooperation between the two parties in the future, achieving mutual benefit and win-win outcomes, and empowering tumor new drug R&D and precision treatment.”
1
About Precision Scientific
Precision Scientific is a new type of platform company driven by ‘multi-omics + data mining,’ focusing on differentiated R&D strategies for innovative drugs. With advanced multi-omics technology, bioinformatics, and AI algorithms at its core, and based on its self-developed, AI-driven massive multi-omics data mining system AIBERT, which took several years to develop, the company provides pharmaceutical and biotech companies with world-leading services in drug mechanism research, biomarker development, biomarker and precision medicine-based differentiated clinical R&D strategies, clinical statistics, central laboratory services, and joint development of drug companion diagnostics. It has already formed deep collaborations with multiple leading domestic and international pharmaceutical and biotech companies, assisting in the R&D and approval of several new drugs in China. Simultaneously, the company also works with its pharmaceutical partners and doctors on the clinical front to provide advanced and precise testing services for Chinese patients, supporting the clinical practice of precision medication.
About Maixin Biotech
Maixin has been deeply rooted in China’s pathology field for 28 years, consistently adhering to independent innovation and providing high-quality diagnostic products and services for Chinese patients. The company has established unique advantages in various aspects, including independent R&D and patent layout, product registration and quality control, academic promotion and customer relationship maintenance, and integration of upstream and downstream resources. The company holds 52 patents of various types, and its laboratory has passed ISO9001 and ISO13485 certifications. It has also received numerous honors, including ‘Fujian Provincial Engineering Technology Research Center for Immunopathology Reagents,’ ‘Fujian Provincial Enterprise Technology Center,’ ‘Fujian Provincial Technology Little Giant Leading Enterprise,’ and ‘National Specialized, Refined, Distinctive, and Innovative Enterprise.’
